Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-000165
Filing Date
2025-01-13
Accepted
2025-01-13 16:16:11
Documents
38
Period of Report
2024-11-30

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20241130x10q.htm   iXBRL 10-Q 688234
2 EX-31.1 bzyr-20241130xex31d1.htm EX-31.1 11729
3 EX-31.2 bzyr-20241130xex31d2.htm EX-31.2 11849
4 EX-32.1 bzyr-20241130xex32d1.htm EX-32.1 6592
5 EX-32.2 bzyr-20241130xex32d2.htm EX-32.2 7022
  Complete submission text file 0001558370-25-000165.txt   2264133

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20241130.xsd EX-101.SCH 17120
7 EX-101.CAL bzyr-20241130_cal.xml EX-101.CAL 17612
8 EX-101.DEF bzyr-20241130_def.xml EX-101.DEF 43964
9 EX-101.LAB bzyr-20241130_lab.xml EX-101.LAB 138070
10 EX-101.PRE bzyr-20241130_pre.xml EX-101.PRE 91217
41 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20241130x10q_htm.xml XML 206232
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0228
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 25526546
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)